| 0.3184 0.07 (28.18%) | 09-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.56 | 1-year : | 0.73 |
| Resists | First : | 0.48 | Second : | 0.62 |
| Pivot price | 0.35  |
|||
| Supports | First : | 0.23 | Second : | 0.19 |
| MAs | MA(5) : | 0.27 |
MA(20) : | 0.35 |
| MA(100) : | 2.24 |
MA(250) : | 13.78 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.6 |
D(3) : | 5.6 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 42.59 | Low : | 0.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SLXN ] has closed above bottom band by 37.2%. Bollinger Bands are 85.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.4 - 0.4 | 0.4 - 0.41 |
| Low: | 0.29 - 0.3 | 0.3 - 0.3 |
| Close: | 0.32 - 0.32 | 0.32 - 0.32 |
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Tue, 29 Sep 2026
Silexion Therapeutics Raises $0.84M Through Warrant Inducement, Hires H.C. Wainwright as Agent - TradingView
Tue, 29 Sep 2026
Silexion raises $837,000 through warrant exercise at reduced price - Investing.com
Tue, 29 Sep 2026
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Tue, 29 Sep 2026
Silexion Therapeutics Announces Exercise of Warrants - GlobeNewswire
Mon, 28 Sep 2026
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Mon, 28 Sep 2026
Silexion reports preclinical data on SIL204 delivery mechanism - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 27.3 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 119 (K) |
| Shares Short P.Month | 13 (K) |
| EPS | -19.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | 31.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|